N-Benzylation of 6-aminoflavone by reductive amination and efficient access to some novel anticancer agents via topoisomerase II inhibition

Mol Divers. 2021 May;25(2):937-948. doi: 10.1007/s11030-020-10079-1. Epub 2020 Apr 5.

Abstract

Series of novel N-benzyl derivatives of 6-aminoflavone (9a-n) were synthesized and evaluated for anticancer and topoisomerase II enzyme inhibition activity. All the synthesized compounds were screened for in vitro anticancer activity against human breast cancer cell line (MCF-7) and human lung cancer cell line (A-549). Among the synthesized compounds, 9f and 9g were found to be the most potent anticancer agents against human breast cancer cell line (MCF-7) with IC50 values of 9.35 µM and 9.58 µM, respectively. Compounds 9b, 9c and 9n exhibited promising anticancer activity against human lung cancer cell line (A-549) with 43.71%, 46.48% and 44.26% inhibition at the highest concentration of 10 µM, respectively. Compounds 9c, 9f and 9g have ability to inhibit the topoisomerase II enzyme. Compound 9f showed most potent topoisomerase II enzyme inhibition activity with IC50 value of 12.11 µM. Further, these compounds have a high potential to be developed as a promising topoisomerase II inhibitors.

Keywords: Aminoflavones; Anticancer agent; Buchwald coupling; Malic acid; Reductive amination; Topoisomerase II enzyme inhibitor.

MeSH terms

  • A549 Cells
  • Amination
  • Antineoplastic Agents* / chemical synthesis
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Cell Survival / drug effects
  • DNA Topoisomerases, Type II / chemistry*
  • Flavonoids* / chemical synthesis
  • Flavonoids* / chemistry
  • Flavonoids* / pharmacology
  • Humans
  • MCF-7 Cells
  • Molecular Docking Simulation
  • Oxidation-Reduction

Substances

  • Antineoplastic Agents
  • Flavonoids
  • aminoflavone
  • DNA Topoisomerases, Type II